title: Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft.
abstract: Breast cancer is one of the most common and feared cancers faced by women. The prognosis of patients with advanced or recurrent breast cancer remains poor despite refinements in multimodality therapies involving chemotherapeutic and hormonal agents. Multimodal therapy with more specific and effective strategy is urgently needed. The oncolytic herpes simplex virus (HSV) has potential to become a new effective treatment option because of its broad host range and tumor selective viral distribution. Bevacizumab is a monoclonal antibody against VEGFA, which inhibits angiogenesis and therefore tumor growth. Our approach to enhance the antitumor effect of the oncolytic HSV is to combine oncolytic HSV HF10 and bevacizumab in the treatment of breast cancer. Our results showed that bevacizumab enhanced viral distribution as well as tumor hypoxia and expanded the population of apoptotic cells and therefore induced a synergistic antitumor effect. HF10 is expected to be a promising agent in combination with bevacizumab in the anticancer treatment.
authors.affiliation: Department of Surgery II, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
authors.forename: Gewen
authors.initials: G
authors.lastname: Tan
authors.forename: Hideki
authors.initials: H
authors.lastname: Kasuya
authors.forename: Tevfik Tolga
authors.initials: TT
authors.lastname: Sahin
authors.forename: Kazuo
authors.initials: K
authors.lastname: Yamamura
authors.forename: Zhiwen
authors.initials: Z
authors.lastname: Wu
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Koide
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Hotta
authors.forename: Toshio
authors.initials: T
authors.lastname: Shikano
authors.forename: Suguru
authors.initials: S
authors.lastname: Yamada
authors.forename: Akiyuki
authors.initials: A
authors.lastname: Kanzaki
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Fujii
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Sugimoto
authors.forename: Shuji
authors.initials: S
authors.lastname: Nomoto
authors.forename: Yoko
authors.initials: Y
authors.lastname: Nishikawa
authors.forename: Maki
authors.initials: M
authors.lastname: Tanaka
authors.forename: Naoko
authors.initials: N
authors.lastname: Tsurumaru
authors.forename: Toshie
authors.initials: T
authors.lastname: Kuwahara
authors.forename: Saori
authors.initials: S
authors.lastname: Fukuda
authors.forename: Toru
authors.initials: T
authors.lastname: Ichinose
authors.forename: Toyone
authors.initials: T
authors.lastname: Kikumori
authors.forename: Shin
authors.initials: S
authors.lastname: Takeda
authors.forename: Akimasa
authors.initials: A
authors.lastname: Nakao
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Kodera
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003131:Combined Modality Therapy; D003588:Cytopathogenic Effect, Viral; D005260:Female; D015870:Gene Expression; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics*; D006801:Humans; D051379:Mice; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics; D018139:Simplexvirus / Q000235:genetics*; D047368:Tumor Burden; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism; D014779:Virus Replication; D023041:Xenograft Model Antitumor Assays
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: HSV; angiogenesis inhibitor; bevacizumab; oncolytic herpes virus HF10